Top 10 Companies in the (S)-(-)-2‑Amino‑4‑pentenoic Acid (CAS 16338‑48‑0) Market (2026): Market Leaders Driving Global Innovation

MARKET INSIGHTS

Global (S)-(-)-2‑Amino‑4‑pentenoic acid (CAS 16338‑48‑0) market size was valued at USD 28.4 million in 2025. The market is forecast to rise from USD 30.1 million in 2026 to USD 52.6 million by 2034, reflecting a CAGR of 7.2 % during the forecast period.

(S)-(-)-2‑Amino‑4‑pentenoic acid, also known as L‑2‑allylglycine or (S)‑allylglycine, is a non‑proteinogenic amino acid bearing an allyl side chain (C₅H₉NO₂). Its dual functionality – an amino group and a terminal alkene – grants it versatility as an intermediate for biologically active compounds, enzyme inhibitors and specialty peptides.

The market is growing steadily as pharmaceutical and biotechnology firms increasingly rely on (S)-(-)-2‑Amino‑4‑pentenoic acid as a chiral synthon in drug discovery pipelines. Academic and industrial research also fuels demand, with growing use in the synthesis of complex natural product analogs and peptidomimetics. Leading fine‑chemical and specialty amino‑acid suppliers – including MilliporeSigma (Merck KGaA), TCI Chemicals and Alfa Aesar – supply this compound worldwide.

(S)-(-)-2‑Amino‑4‑pentenoic Acid (CAS 16338‑48‑0) Market – View in Detailed Research Report

Top 10 Companies in the (S)-(-)-2‑Amino‑4‑pentenoic Acid Market

1. MilliporeSigma (Merck KGaA)

Headquarters: Rahway, New Jersey, USA
Key Offering: Research‑grade and GMP‑grade (S)-(-)-2‑Amino‑4‑pentenoic acid, supporting peptide synthesis and medicinal chemistry.

MilliporeSigma’s long‑standing reputation in the life‑sciences market ensures rapid access to high‑purity chiral intermediates. Their integrated quality‑management system and global distribution network provide consistent supply for both academic labs and pharmaceutical developers.

Sustainability & Growth Initiatives:

• Investments in green chemistry for chiral synthesis, reducing solvent use and waste.
• Expansion of contract‑manufacturing capabilities to meet rising demand from early‑stage drug development.
• Collaboration with academic institutions to validate new synthetic routes for complex peptides.

2. Combi‑Blocks Inc.

Headquarters: New York, NY, USA
Key Offering: Custom‑synthesized chiral building blocks, including (S)-(-)-2‑Amino‑4‑pentenoic acid.

Combi‑Blocks specializes in on‑demand synthesis of niche amino‑acid derivatives, offering rapid turnaround and flexible scale. Their expertise in asymmetric catalysis positions them as a preferred partner for companies developing stapled peptides.

Sustainability & Growth Initiatives:

• Implementation of continuous‑flow synthesis to improve efficiency and reduce energy consumption.
• Partnerships with universities to explore novel biocatalytic routes.
• Expansion of their API portfolio to include additional enantiomerically defined intermediates.

3. Ark Pharm, Inc.

Headquarters: Carlsbad, CA, USA
Key Offering: Catalog of research‑grade (S)-(-)-2‑Amino‑4‑pentenoic acid and related chiral amino acids.

Ark Pharm provides high‑purity compounds for academic and industrial research, emphasizing rigorous analytical validation. Their focus on niche markets allows them to maintain tight control over supply chain quality.

Sustainability & Growth Initiatives:

• Adoption of renewable feedstocks for allyl‑bearing intermediates.
• Development of scalable, single‑pot synthesis processes to reduce solvent waste.
• Strengthening of regulatory compliance documentation to support GMP‑grade production.

4. AK Scientific, Inc.

Headquarters: Cambridge, MA, USA
Key Offering: Research‑grade (S)-(-)-2‑Amino‑4‑pentenoic acid with high optical purity.

AK Scientific delivers a broad range of specialty chemicals, with a focus on clean‑room manufacturing and detailed impurity profiling. Their laboratory‑grade products are favored by academic chemists for mechanistic studies.

Sustainability & Growth Initiatives:

• Investment in low‑energy chiral resolution techniques.
• Collaboration with CROs to provide on‑demand synthesis for early‑stage projects.
• Expansion of their analytical services to support end‑user quality assurance.

5. Fluorochem Ltd.

Headquarters: Cambridge, UK
Key Offering: Research‑grade (S)-(-)-2‑Amino‑4‑pentenoic acid and a portfolio of fluorinated amino‑acid analogs.

Fluorochem’s expertise in fine‑chemical synthesis and quality control makes it a reliable source for high‑purity chiral intermediates. Their focus on fluorinated compounds supports emerging drug discovery programs.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recycling systems.
• Development of scalable chiral synthesis routes using organocatalysts.
• Partnerships with contract manufacturers to extend production capacity.

6. Watanabe Chemical Industries, Ltd.

Headquarters: Osaka, Japan
Key Offering: Custom synthesis of chiral amino acids, including (S)-(-)-2‑Amino‑4‑pentenoic acid, for pharmaceutical intermediates.

Watanabe Chemical Industries offers precision synthesis with a focus on process scalability and regulatory compliance, serving both domestic and international clients.

Sustainability & Growth Initiatives:

• Adoption of enzyme‑mediated resolution to reduce hazardous reagents.
• Expansion of their GMP facilities to accommodate larger batch sizes.
• Collaboration with academic groups to validate new synthetic pathways.

7. Tokyo Chemical Industry Co., Ltd. (TCI)

Headquarters: Tokyo, Japan
Key Offering: Research‑grade (S)-(-)-2‑Amino‑4‑pentenoic acid with a focus on high enantiomeric excess.

TCI’s reputation for high‑purity specialty chemicals and strong analytical capabilities makes it a go‑to supplier for researchers requiring stringent purity standards.

Sustainability & Growth Initiatives:

• Investment in chiral chromatography technologies to streamline purification.
• Development of rapid‑screening protocols for new chiral intermediates.
• Expansion of their online ordering platform to improve accessibility.

8. Hangzhou Dayangchem Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: Research‑grade (S)-(-)-2‑Amino‑4‑pentenoic acid produced via cost‑effective asymmetric synthesis.

Hangzhou Dayangchem leverages China’s manufacturing capabilities to supply high‑purity chiral building blocks at competitive prices, supporting both domestic and export markets.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient synthesis processes.
• Partnerships with local universities to develop new catalytic systems.
• Strengthening of quality‑management systems to meet international GMP standards.

9. Jiangsu Quality Horizons Pharmtech Co., Ltd.

Headquarters: Jiangsu, China
Key Offering: Custom and catalog production of (S)-(-)-2‑Amino‑4‑pentenoic acid for pharmaceutical research.

Jiangsu Quality Horizons Pharmtech focuses on rapid, scalable synthesis of chiral intermediates, with an emphasis on meeting the evolving needs of contract research organizations.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in synthesis routes.
• Expansion of their analytical services to support end‑user validation.
• Collaboration with international CROs to broaden market reach.

Download FREE Sample Report

(S)-(-)-2‑Amino‑4‑pentenoic Acid (CAS 16338‑48‑0) Market – View in Detailed Research Report

Get Full Report

(S)-(-)-2‑Amino‑4‑pentenoic Acid (CAS 16338‑48‑0) Market – View in Detailed Research Report

Outlook

The market is poised for continued expansion as the demand for chiral building blocks in peptide therapeutics and chemical biology remains strong. The rise of stapled peptides and macrocyclic drug candidates, coupled with increased investment in precision medicine, is expected to drive upstream consumption of (S)-(-)-2‑Amino‑4‑pentenoic acid. Simultaneously, academic research into enzyme mechanisms and neuropharmacology will sustain a steady base of demand for high‑purity material.

Future Trends

Emerging synthetic platforms – such as biocatalytic resolution and continuous‑flow asymmetric synthesis – are likely to lower production costs and improve scalability, making (S)-(-)-2‑Amino‑4‑pentenoic acid more accessible to a broader range of users. The integration of bioorthogonal chemistry into drug discovery pipelines will further elevate the compound’s utility, while advances in analytical techniques will tighten purity specifications, reinforcing the importance of suppliers that can deliver well‑characterized, GMP‑grade material.